Laddar...
The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia
Adults with relapsed/refractory B-acute lymphoblastic leukemia (ALL) have a complete remission (CR) rate of 20–45% and median overall survival of 3–9 months, depending on the duration of the first remission and number of lines of salvage therapy. Allogeneic hematopoietic stem cell transplantation (a...
Sparad:
| I publikationen: | Ther Adv Hematol |
|---|---|
| Huvudupphovsmän: | , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
SAGE Publications
2016
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4872177/ https://ncbi.nlm.nih.gov/pubmed/27247755 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620716640422 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|